| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RCL |
| Uniprot No | O43598 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-174aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAAMVPGRSESWERGEPGRPALYFCGSIR GGREDRTLYERIVSRLRRFGTVLTEHVAAAELGARGEEAAGGDRLIHEQD LEWLQQADVVVAEVTQPSLGVGYELGRAVAFNKRILCLFRPQSGRVLSAM IRGAADGSRFQVWDYEEGEVEALLDRYFEADPPGQVAASPDPTT |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组蛋白(假设RCL为重组蛋白相关技术)的示例参考文献。由于“RCL重组蛋白”可能是特定领域术语，建议通过学术数据库(如PubMed、Google Scholar)进一步验证关键词：
---
1. **《Optimization of Recombinant Protein Expression in E. coli: Strategies and Challenges》**
*作者：Smith J, Lee T.*
摘要：探讨在大肠杆菌系统中表达重组蛋白的优化策略，包括启动子选择、密码子优化和培养条件调控，以提高RCL重组蛋白的产量和稳定性。
2. **《Recombinant Collagen-Based Biomaterials for Tissue Engineering Applications》**
*作者：Zhang Y, et al.*
摘要：研究利用重组胶原蛋白(RCL)开发的新型生物材料，分析其生物相容性和力学性能，证明其在皮肤再生和3D生物打印中的潜在应用价值。
3. **《High-Efficiency Purification of Recombinant Proteins Using Affinity Tag Systems》**
*作者：Kumar R, Patel A.*
摘要：比较不同亲和标签(如His-tag、GST-tag)对RCL重组蛋白纯化效率的影响，提出一种新型串联纯化方法以提升目标蛋白的回收率。
4. **《Structural and Functional Characterization of a Recombinant Viral Envelope Protein》**
*作者：Chen L, et al.*
摘要：通过X射线晶体学解析一种重组病毒包膜蛋白(RCL)的三维结构，验证其抗原性，为后续疫苗研发提供理论依据。
---
**注意**：以上文献为示例性质，具体研究需根据实际关键词检索。建议使用“重组蛋白”(recombinant protein)结合应用领域(如疫苗、胶原蛋白、纯化技术)进行精准查找。
RCL recombinant proteins are a class of engineered proteins produced through advanced molecular biology techniques, primarily for biomedical research, therapeutic development, and diagnostic applications. The term "RCL" may refer to proprietary platforms or standardized systems (e.g., "Recombinant Cell Line") optimized for high-yield, consistent protein expression. These proteins are generated by cloning target genes into expression vectors, which are then transfected into host cells like mammalian (e.g., CHO, HEK293), bacterial, or insect cells. Post-translational modifications critical for protein functionality—such as glycosylation or folding—are achieved using mammalian systems like Expi293 cells, a common choice for RCL workflows due to their human-like modification machinery.
The development of RCL recombinant proteins gained momentum in the 2000s, driven by demands for precision in biologics, such as monoclonal antibodies, enzymes, and viral antigens. Unlike traditional protein extraction methods, RCL technology ensures scalability, reproducibility, and reduced contamination risks from animal-derived components. Quality control involves rigorous analytics (HPLC, mass spectrometry) to verify purity, structure, and bioactivity. Applications span drug discovery (e.g., targeting cancer or immune disorders), vaccine production (e.g., SARS-CoV-2 spike proteins), and diagnostic kits (e.g., ELISA standards). Challenges include optimizing expression conditions and minimizing immunogenic elements. As personalized medicine advances, RCL platforms continue to evolve, integrating CRISPR gene editing and AI-driven design to enhance protein efficacy and manufacturing efficiency.
×
